Assay

Accelerating Vaccines to Clinical Trials -- A Toolkit for Efficacy, Safety and Bioanalytical Studies, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, November 1, 2023

TORONTO, Nov. 1, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar delving into the evolution of vaccine platform technologies to the current era of mRNA vaccines, with a discussion on the unique challenges they face in their advancements to clinical trials. The experts, Dr. Narendra Deshmukh and Dr. Kedar Purnapatre will discuss some of the many challenges facing the vaccine development industry today in the demonstration of product quality, immunogenicity and safety. They will share their experience working with various vaccine and adjuvant types emphasizing the importance of appropriately designed experiments, biomarker selection and choice of appropriate bioassays and bioanalytical tools.

Key Points: 
  • In this free webinar, learn about the evolution of vaccine technologies over several decades, culminating in the current era of mRNA vaccines.
  • Attendees will gain insights into the unique challenges associated with different vaccine platform technologies, particularly in terms of assessing product quality, immunogenicity and safety.
  • Join this webinar to gain insights into the challenges and innovations in mRNA vaccines in clinical trials.
  • Join experts from Aragen Life Sciences , Dr. Narendra Deshmukh, Executive Director; and Dr. Kedar Purnapatre, Director, Bioanalytical & Bioassay, for the live webinar on Wednesday, November 15, 2023, at 11am EST (4pm GMT/UK).

Microbix Presents Results of STI Test Controls at AACC

Retrieved on: 
Monday, July 24, 2023

At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.

Key Points: 
  • At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.
  • Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and molecular (i.e., “PCR”) tests and their workflows.
  • Microbix therefore developed a whole-workflow multiplex STI QAP desiccated on a Copan FLOQSwab® that is stable at 2-30°C and contains inactive whole-genome target pathogens.
  • We’re pleased to be offering Microbix QAPs to support clinically-important STI testing – as tools for validation, verification, and training, as external quality assessment samples, and as in-kit controls.”

Global Proteomic Biomarker Analytics Market Report 2023 with Executive & Consultant Guides - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 8, 2023

The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Where genomics couldn't find all the answers proteomics is stepping up to the plate.
  • Proteomic Biomarker Analytics is just finding its feet, but the opportunity is to understand the front line players, the actual proteins and protein complexes, that do the work of managing cellular life.
  • The report forecasts the market size out for five years for a number of different market segments.

Global Proteomic Biomarker Analytics Market Research Report 2023: There is Plenty of Opportunity, and Some Completely New Types of Biomarkers are Already at Work

Retrieved on: 
Wednesday, May 31, 2023

DUBLIN, May 31, 2023 /PRNewswire/ -- The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 31, 2023 /PRNewswire/ -- The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Where genomics couldn't find all the answers proteomics is stepping up to the plate.
  • Proteomic Biomarker Analytics is just finding its feet, but the opportunity is to understand the front line players, the actual proteins and protein complexes, that do the work of managing cellular life.
  • The report forecasts the market size out for five years for a number of different market segments.

Global Proteomic Biomarker Analytics Markets Report 2023 with Executive and Consultant Guides, Including Customized Forecasting and Analysis 2022 to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 24, 2023

With Executive and Consultant Guides, Including Customized Forecasting and Analysis.

Key Points: 
  • With Executive and Consultant Guides, Including Customized Forecasting and Analysis.
  • 2022 to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report forecasts the market size out for five years for a number of different market segments.
  • Get the publisher's research team working for you by ordering all, or a portion, of this comprehensive report.

Developing and Validating Robust Cell-Based Assays for GMP QC Testing, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, May 25, 2023

TORONTO, May 25, 2023 /PRNewswire-PRWeb/ -- Cell-based assays in developing cutting-edge therapeutics have become increasingly important in recent years. With advancements in technology and the US Food and Drug Administration (FDA)'s removal of animal testing requirements, cell-based assays for QC testing have become a crucial component in the drug development process to demonstrate efficacy and potency.

Key Points: 
  • Attendees will learn about cell-based potency assays fit for GMP QC testing.
  • TORONTO, May 25, 2023 /PRNewswire-PRWeb/ -- Cell-based assays in developing cutting-edge therapeutics have become increasingly important in recent years.
  • The relevance of cell-based assays is that they are customizable and can be tailored to specific needs.
  • The use of cell-based assays has the potential to revolutionize growing therapeutic areas, allowing for the development of more targeted and effective drugs.

Ozette Announces New Suite of Machine Learning-Powered Computational Analysis Solutions Coupled with High Dimensional Full Spectrum Cytometry Data Generation to Accelerate Decision-Making for Clinical Biomarker Teams

Retrieved on: 
Thursday, May 18, 2023

Ozette Assay-to-Insights combines three technologies developed by the company: world-class data generation at the Ozette Laboratory under Good Clinical Laboratory Practices (GCLP) guidelines; rapid computational monitoring of pre-defined biomarker endpoints using Ozette Endpoints™; and unbiased discovery and annotation of single-cell cytometry data through Ozette Discovery™.

Key Points: 
  • Ozette Assay-to-Insights combines three technologies developed by the company: world-class data generation at the Ozette Laboratory under Good Clinical Laboratory Practices (GCLP) guidelines; rapid computational monitoring of pre-defined biomarker endpoints using Ozette Endpoints™; and unbiased discovery and annotation of single-cell cytometry data through Ozette Discovery™.
  • Insights generated from Ozette Endpoints™ and Ozette Discovery™ are made available through the Ozette Platform™, a cloud-based system that enables clinical teams to interact and explore cytometry data in a central dashboard.
  • Ozette Endpoints™ provides clinical biomarker teams with rapid access to decision-enabling data.
  • Ozette Discovery™ provides best-in-class, unbiased, robust, and transparent automated cell population discovery and annotation from single-cell cytometry data.

AskBio Announces 11 Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting in 2023

Retrieved on: 
Thursday, May 11, 2023

AskBio presentations cover pre-clinical research into immune responses to AAV, data on methods to improve the efficacy of AAV-gene therapy and research into improved analytics and bioassays.

Key Points: 
  • AskBio presentations cover pre-clinical research into immune responses to AAV, data on methods to improve the efficacy of AAV-gene therapy and research into improved analytics and bioassays.
  • By targeting these therapy areas, AskBio aims to deliver breakthrough treatments that could benefit more than 35 million patients worldwide.1–7
    AskBio's presentations at ASGCT include:
    A Platform Approach for Adeno-Associated Virus Manufacturing to Support Gene Therapy Products.
  • Presented by Audry Fernandez, R&D, Asklepios BioPharmaceutical, Inc. [Oral presentation: 16:00 May 18 (Room 411)]
    Impact of Genetic Diversity on Gene Therapy Efficacy.
  • Presented by Sandro Alves, Head preclinical (France), Asklepios BioPharmaceutical, Inc. [Poster presentation: 12:00 May 19 (Poster #1261)]

Agilent Showcases Comprehensive Cancer Portfolio Solutions at AACR 2023

Retrieved on: 
Friday, April 14, 2023

Cancer is the second most common cause of death in the US, and the incidence continues to increase, with over 1.9 million new cancer cases expected to be diagnosed in 2023.

Key Points: 
  • Cancer is the second most common cause of death in the US, and the incidence continues to increase, with over 1.9 million new cancer cases expected to be diagnosed in 2023.
  • An estimated 41 out of 100 men and 39 out of 100 women will potentially develop cancer during their lifetime1.
  • “Cancer remains a significant area of strategic focus for Agilent.
  • AACR poster sessions will include multiple Agilent research posters and more than 50 additional customer posters featuring Agilent instruments and solutions.

GTP Bioways and Texcell announce a business partnership to provide extended services to biopharmaceutical companies worldwide

Retrieved on: 
Thursday, March 9, 2023

With this unique partnership, the two French players aim at offering end-to-end services to support the development of innovative therapeutics worldwide.

Key Points: 
  • With this unique partnership, the two French players aim at offering end-to-end services to support the development of innovative therapeutics worldwide.
  • Through this unique collaboration, GTP and Texcell aim to provide comprehensive support to biopharmaceutical companies throughout their clinical development.
  • It is thus quite natural that our long business relationship turned into a deeper partnership," says Alain Sainsot, president of GTP Bioways.
  • With this partnership, GTP Bioways and Texcell wish to reinforce their support to biopharmaceutical companies worldwide in helping them hasten their time to clinics and to market.